Lorlatinib as a treatment for ALK-positive lung cancer

被引：16

作者：

Baba, Keisuke ^{[1
]}

Goto, Yasushi ^{[1
]}

机构：

[1] Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tokyo, Japan

来源：

FUTURE ONCOLOGY | 2022年 / 18卷 / 24期

关键词：

brain metastasis; pharmacodynamics; pharmacokinetics; real-world data; resistance; treatment sequence; ANAPLASTIC LYMPHOMA KINASE; PATIENT-REPORTED OUTCOMES; ACQUIRED-RESISTANCE; REARRANGED NSCLC; PRIOR EXPOSURE; OPEN-LABEL; CELL; INHIBITORS; CRIZOTINIB; MUTATION;

D O I：

10.2217/fon-2022-0184

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, has been approved as a treatment for ALK-positive lung cancer. This review provides information regarding the pharmacology and clinical features of lorlatinib, including its efficacy and associated adverse events. Pivotal clinical trials are discussed along with the current status of lorlatinib as a treatment for ALK-positive lung cancer and future therapeutic challenges. Plain language summary Lorlatinib has been approved as a new standard treatment for lung cancer with gene alteration known as ALK fusion. This review provides information regarding the characteristics of lorlatinib, including its efficacy and the unexpected medical problems that occur during treatment. Today, treatment of ALK-positive lung cancer is more complicated because of the active development of drugs like lorlatinib. This review demonstrates the logic of including lorlatinib as part of the treatment plan and sheds light on the future of treatment for ALK-positive lung cancer.

引用

页码：2745 / 2766

页数：22

共 172 条

[1]

American CancerSociety, LUNG CANC SURV RAT

[2] Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis [J].

Ando, Koichi ;

Manabe, Ryo ;

Kishino, Yasunari ;

Kusumoto, Sojiro ;

Yamaoka, Toshimitsu ;

Tanaka, Akihiko ;

Ohmori, Tohru ;

Sagara, Hironori .

CANCERS, 2021, 13 (15)

[3]

[Anonymous], 2016, Cancer Discov, V6, pOF7, DOI [10.1158/2159-8290.CD-NB2016-044, 10.1158/2159-8290.CD-NB2016-076]

[4]

[Anonymous], 2018, CA Cancer J Clin, DOI DOI 10.3322/caac.20115

[5] Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer [J].

Arai, Sachiko ;

Takeuchi, Shinji ;

Fukuda, Koji ;

Taniguchi, Hirokazu ;

Nishiyama, Akihiro ;

Tanimoto, Azusa ;

Satouchi, Miyako ;

Yamashita, Kaname ;

Ohtsubo, Koshiro ;

Nanjo, Shigeki ;

Kumagai, Toru ;

Katayama, Ryohei ;

Nishio, Makoto ;

Zheng, Mei-mei ;

Wu, Yi-Long ;

Nishihara, Hiroshi ;

Yamamoto, Takushi ;

Nakada, Mitsutoshi ;

Yano, Seiji .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (05) :752-765

[6] Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation [J].

Baglivo, Sara ;

Ricciuti, Biagio ;

Ludovini, Vienna ;

Metro, Giulio ;

Siggillino, Annamaria ;

De Giglio, Andrea ;

Chiari, Rita .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) :E145-E147

[7] Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper [J].

Barata, Fernando ;

Aguiar, Carlos ;

Marques, Tiago Reis ;

Marques, Jose Bravo ;

Hespanhol, Venceslau .

DRUG SAFETY, 2021, 44 (08) :825-834

[8] First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib [J].

Basit, Sulman ;

Ashraf, Zaman ;

Lee, Kwangho ;

Latif, Muhammad .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 134 :348-356

[9] Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer [J].

Bauer, Todd M. ;

Shaw, Alice T. ;

Johnson, Melissa L. ;

Navarro, Alejandro ;

Gainor, Justin F. ;

Thurm, Holger ;

Pithavala, Yazdi K. ;

Abbattista, Antonello ;

Peltz, Gerson ;

Felip, Enriqueta .

TARGETED ONCOLOGY, 2020, 15 (01) :55-65

[10] Clinical Management of Adverse Events Associated with Lorlatinib [J].

Bauer, Todd M. ;

Felip, Enriqueta ;

Solomon, Benjamin J. ;

Thurm, Holger ;

Peltz, Gerson ;

Chioda, Marc D. ;

Shaw, Alice T. .

ONCOLOGIST, 2019, 24 (08) :1103-1110

← 1 2 3 4 5 6 7 8 9 10 →